Ryan S D'Souza1, Ross Barman1, Amira Joseph1, Alaa Abd-Elsayed2. 1. Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA. 2. Department of Anesthesiology and Perioperative Medicine, University of Wisconsin, Madison, WI, USA. abdelsayed@wisc.edu.
Abstract
PURPOSE OF REVIEW: Painful diabetic neuropathy (PDN) manifests with pain typically in the distal lower extremities and can be challenging to treat. The authors appraised the literature for evidence on conservative, pharmacological, and neuromodulation treatment options for PDN. RECENT FINDINGS: Intensive glycemic control with insulin in patients with type 1 diabetes may be associated with lower odds of distal symmetric polyneuropathy compared to patients who receive conventional insulin therapy. First-line pharmacologic therapy for PDN includes gabapentinoids (pregabalin and gabapentin) and duloxetine. Additional pharmacologic modalities that are approved by the Food and Drug Administration (FDA) but are considered second-line agents include tapentadol and 8% capsaicin patch, although studies have revealed modest treatment effects from these modalities. There is level I evidence on the use of dorsal column spinal cord stimulation (SCS) for treatment of PDN, delivering either a 10-kHz waveform or tonic waveform. In summary, this review provides an overview of treatment options for PDN. Furthermore, it provides updates on the level of evidence for SCS therapy in cases of PDN refractory to conventional medical therapy.
PURPOSE OF REVIEW: Painful diabetic neuropathy (PDN) manifests with pain typically in the distal lower extremities and can be challenging to treat. The authors appraised the literature for evidence on conservative, pharmacological, and neuromodulation treatment options for PDN. RECENT FINDINGS: Intensive glycemic control with insulin in patients with type 1 diabetes may be associated with lower odds of distal symmetric polyneuropathy compared to patients who receive conventional insulin therapy. First-line pharmacologic therapy for PDN includes gabapentinoids (pregabalin and gabapentin) and duloxetine. Additional pharmacologic modalities that are approved by the Food and Drug Administration (FDA) but are considered second-line agents include tapentadol and 8% capsaicin patch, although studies have revealed modest treatment effects from these modalities. There is level I evidence on the use of dorsal column spinal cord stimulation (SCS) for treatment of PDN, delivering either a 10-kHz waveform or tonic waveform. In summary, this review provides an overview of treatment options for PDN. Furthermore, it provides updates on the level of evidence for SCS therapy in cases of PDN refractory to conventional medical therapy.
Authors: Peter J Dyck; Carol J Overland; Phillip A Low; William J Litchy; Jenny L Davies; P James B Dyck; Rickey E Carter; L Joseph Melton; Henning Andersen; James W Albers; Charles F Bolton; John D England; Christopher J Klein; Gareth Llewelyn; Michelle L Mauermann; James W Russell; Dinesh Selvarajah; Wolfgang Singer; A Gordon Smith; Solomon Tesfaye; Adrian Vella Journal: Arch Neurol Date: 2012-12
Authors: Peter J Dyck; James W Albers; Henning Andersen; Joseph C Arezzo; Geert-Jan Biessels; Vera Bril; Eva L Feldman; William J Litchy; Peter C O'Brien; James W Russell Journal: Diabetes Metab Res Rev Date: 2011-10 Impact factor: 4.876
Authors: Rodica Pop-Busui; Andrew J M Boulton; Eva L Feldman; Vera Bril; Roy Freeman; Rayaz A Malik; Jay M Sosenko; Dan Ziegler Journal: Diabetes Care Date: 2017-01 Impact factor: 19.112
Authors: Ryan S D'Souza; Eva Kubrova; Yeng F Her; Ross A Barman; Brandon J Smith; Gabriel M Alvarez; Tyler E West; Alaa Abd-Elsayed Journal: Adv Ther Date: 2022-08-22 Impact factor: 4.070